Company intelligence / Profile preview

IASON

Seiersberg, Styria, Austriaiasonltd.com ↗

Ownership: Private
Employees: ~50
Development stage: Other

Overview

IASON specializes in the production and distribution of radioactive pharmaceuticals for positron emission tomography (PET), having introduced this method to Austria in 1997. The company manufactures its own products and supplies them to nuclear medicine and laboratory medicine sectors throughout Europe. In June 2021, it was acquired by Curium and integrated into a network of 27 PET sites across Europe.

Therapeutic areas: OncologyCardiovascularNeurology
Modalities: Radiopharmaceuticals
Industry: Medical Imaging

Beyond the preview

Go deeper on IASON.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IASON.

Explore the full profile